Predicting Effective Therapy in Pancreatic Cancer

Memorial Sloan Kettering Cancer Center (MSK)

Status: Active, not recruiting

Conditions: Pancreatic Adenocarcinoma; Pancreatic Cancer

Treatments: Diagnostic Test: CTC isolocation and analysis

Study type: Observational

Funder types: Other

Identifiers

NCT03033927

17-042

Details and patient eligibility

About

The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.

Enrollment: 74 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at MSKCC, AJCC stage IV disease at time of enrollment.
• Patient planning to receive treatment with FOLFIRINOX or gem/nab-P chemotherapy, with or without investigational agents.
• Prior surgery, chemotherapy and/or radiation therapy for AJCC Stage I-III pancreatic adenocarcinoma is permitted.
• ECOG performance status 0-2.
• A minimum age of 18 years old.

Exclusion criteria

• Prior chemotherapy for AJCC stage IV pancreatic adenocarcinoma
• Known to be HIV positive on antiretroviral therapy
• Prior organ allograft
• Any medical or psychiatric condition that may interfere with the ability to comply with protocol procedures

Trial design

74 participants in 1 patient group

Participants with Stage IV Pancreatic Cancer

Treatment:

Diagnostic Test: CTC isolocation and analysis